Aclarion expands Nociscan availability in Los Angeles via Institute of Neuro Innovation agreement

Aclarion, Inc.

Aclarion, Inc.

ACON

0.00
  • Aclarion expanded Nociscan availability in the greater Los Angeles area via an agreement with the Institute of Neuro Innovation.
  • Partnership targets real-world evidence on chronic low back pain, comparing Nociscan chemical biomarker data with SPECT-CT bone metabolic findings.
  • Move supports a scalable growth strategy, aiming to build data assets to drive payer coverage and provider adoption.
  • Nociscan is positioned to help pinpoint painful lumbar discs, citing a 97% surgical success rate when all Nociscan-positive discs are treated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.